Dipeptidyl peptidase IV (DPP-IV) inhibitor. Inhibits hydrolysis of incretins, regulating blood glucose levels. Induces Src and vascular endothelium-cadherin phosphorylation, increasing vascular permeability in the retina. Also increases number of viable phenotypic long term repopulating hematopoietic stem cells when harvesting mouse bone marrow in aerobic conditions.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Dipeptidyl peptidase IV and its inhibitors: therapeutics for type 2 diabetes and what else?
Juillerat-Jeanneret et al.
Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation.
Lim et al.
Korean J.Intern.Med., 2015;30:759
Dipeptidyl peptidase-4 inhibitor increases vascular leakage in retina through VE-cadherin phosphorylation.
Lee et al.